Acknowledgments
This article was published in a supplement sponsored by UCB Pharma SpA, Italy. The supplement was guest edited by Daniel Aletaha and peer reviewed by Leonard H. Calabrese who both received a small honorarium from Springer Healthcare to cover out-of-pocket expenses. D.A. has received honoraria and research grants from UCB, and honoraria from Abbvie, Grünenthal, Janssen, Merck, Medac, Mitsubishi Tanabe, Pfizer, AstraZeneca, Eli Lilly, Novo Nordisk, and Sanofi/Regeneron. L.H.C. has consulted for UCB, Roche, Janssen, Pfizer and BMS.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Aletaha, D. How FABulous is PEGgy? Certoliziumab Pegol from the Bench to the Patients. BioDrugs 28 (Suppl 1), 3–4 (2014). https://doi.org/10.1007/s40259-013-0067-9
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40259-013-0067-9